

Attn: Dr. Henning Gädeke
c/o Dr. Michael MAKANGA
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

29th August 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of BIOFABRI S.L.U., registered office at Pol. Ind. La Relva, 36410 Porrino, Spain, VAT nº B27712561 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Introduction to the organisation, in particular its common objectives with Global Health EDCTP3 JU

Biofabri is a biopharmaceutical company created in 2008 with the aim of researching, developing, and manufacturing vaccines for humans. With an extensive technical and scientific capacity in vaccines and immunotherapy, Biofabri belongs to the Zendal group, a Spanish pharmaceutical business group made up of six companies specializing in the development, manufacture and marketing of vaccines and other biotechnological products for human and animal health. Biofabri is developing MTBVAC, a novel and highly promising new vaccine against tuberculosis. Tuberculosis (TB), as the leading infectious disease killer in the world, disproportionately affects low- and middle-income countries, particularly in the Africa and Southeast Asia regions. Currently, there are over 10.8 million new cases and 1.25 million deaths annually due to TB. Despite advances in treatment, the disease burden persists, exacerbated by drug resistance and high co-infection rates with HIV. Biofabri aims to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU) to enable MTBVAC to advance through late-stage clinical trials in infants and adolescents and adults and to generate key data to support licensure and widespread deployment in those countries most impacted by TB.

Global Health EDCTP3 JU topic.

This application relates to topic: HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage and Type of action: HORIZON-JU-RIA (HORIZON JU Research and Innovation Actions), to proposal number: SEP-211145528 and Proposal acronym: MTBVAC-AVANTE. The goal of the MTBVAC-AVANTE consortium is to advance MTBVAC through Phase 2b development in adolescents and adults and through Phase 3 development in infants, while generating key data to support licensure and widespread deployment in those countries most impacted by TB. The consortium aims to achieve this goal through the conduct of two late-stage trial, which will generate clinical evidence of MTBVAC’s efficacy in preventing pulmonary TB, and of its safety and immunogenicity in adolescents and adults living in TB-endemic countries in sub-Saharan Africa. Moreover, we will demonstrate MTBVAC’s improved efficacy compared to BCG in preventing TB disease in neonates born to HIV-infected and -uninfected mothers. We will also ensure the timely translation of findings into public health practice and policy, by defining regulatory pathways to accelerate widespread availability for the use of MTBVAC in adolescents and adults and as a BCG alternative in neonates; and ensure generated evidence contributes to widespread adoption in SSA and

beyond, in consultation with communities and regional and local authorities. The consortium coordinated by Biofabri will bring together a diverse group of European and African partners, including non-for-profit product development partnerships (TBVI and IAVI), universities (University of Zaragoza, University of Cape Town, University of Cape Town Lung Institute) and experienced sub-Saharan African clinical research centers (Enhancing Care Foundation (ECF), South African Tuberculosis Vaccine Initiative (SATVI), Wits Health Consortium (WITS VIDA), Kenya Medical Research institute (KEMRI), and Ifakara Health Institute (IHI).

Contribution to Global Health EDCTP3 JU, outlining its relevance, type (IKOP and/or FC), duration and potential added value for the achievement of the objectives of the Global Health EDCTP3 JU.

The MTBVAC-AVANTE project presents two complementary clinical development lines or sub-projects:

1. Phase 2b in A&A in SSA: The **IMAGINE** trial is a Phase 2b, double-blind, randomized, placebo-controlled trial to evaluate the efficacy, safety and immunogenicity of a candidate TB vaccine, MTBVAC, against TB disease in A&A aged 14-45 years, living in a TB endemic region (NCT06272812).
2. Phase 3 in infants in SSA: **MTBVACN3** is a randomised, double-blind, controlled Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of MTBVAC in 7120 healthy HIV unexposed (HU) and HIV-exposed uninfected (HEU) infants in tuberculosis-endemic regions of SSA (NCT04975178).

Biofabri will contribute to the development of the following activities:

For the Phase 3 in infants in SSA - MTBVACN3 -, the total estimated budget amounts to EUR **22.495.385,79**. Of this, a contribution of EUR 6.229.336,95 is being requested from EDCTP3, which represents approximately 28% of the total budget of this sub-project (22.495.385,79)

Biofabri hereby commits to ensuring the financing of the remaining EUR 16.266.048,84 required for this sub-project, of which EUR 7.032.677,03 will be supported through HADEA (European Commission). The balance 9.233.371,8 EUR will be directly financed by Biofabri as follows:

1. Co-funding in the form of Financial Contribution (FC) to support the clinical trial activities carried out by the clinical sites (SATVI, ECF, WITS VIDA) and Universidad de Zaragoza involved in the Phase 3 trial in newborns (EUR 7.014.947,51). This co-funding is essential to ensure that the clinical trial activities in these sites can be carried out as planned.
2. Co-funding in the form of in-kind Operational Contribution (IKOP) to support essential activities ensuring the adequate performance of the project and the timely licensure and subsequent widespread deployment of MTBVAC, such as Project Management, Clinical Trial Monitoring (CRO Subcontracting), Statistics, Regulatory activities, Stakeholder engagement. (EUR 2.218.424,29).

	2026	2027	2028	2029	2030	TOTAL
Co-funding (FC)	2.500.319,31	2.708.008,23	1.806.619,97	0	0	7.014.947,51
Co-funding (IKOP)	1.343.811,01	123.575,50	604.254,05	146.783,73	0	2.218.424,29
Total	3.844.130,32	2.831.583,73	2.410.874,02	146.783,73	0	9.233.371,8

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Esteban Rodríguez
CEO of BIOFABRI S.L.U.
Legal Representative

Date: 29th August 2025

Firmado por: Esteban Rodríguez Sánchez
Fecha y hora: 29-08-2025 10:52 UTC+2
Correo electrónico: e.rodriguez@biofabri.es